Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV
| Autor: | G M Connolly, Don Smith, Jennifer Midgley, Mhairi Allan, Brian Gazzard |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty Antifungal Agents Nausea Itraconazole medicine.medical_treatment Immunology HIV Infections Opportunistic Infections Esophageal Diseases Gastroenterology law.invention Randomized controlled trial Double-Blind Method law Candidiasis Oral Recurrence Internal medicine medicine Immunology and Allergy Humans Mycosis Chemotherapy business.industry Candidiasis medicine.disease Rash Surgery Infectious Diseases Ketoconazole Toxicity Female medicine.symptom business medicine.drug |
| Zdroj: | AIDS (London, England). 5(11) |
| ISSN: | 0269-9370 |
| Popis: | To determine the efficacy and toxicity of two systemically active antifungal agents in the treatment of buccal and oesophageal candidiasis 111 HIV-infected patients with microscopically-confirmed candidiasis were randomized to receive either 200 mg itraconazole once a day or 200 mg ketoconazole twice a day for 28 days in a double blind study. After 1 week of treatment, 75 and 82% of the patients on itraconazole and ketoconazole, respectively, had responded clinically. After 4 weeks of treatment, this had risen to 93% in each group. One patient discontinued itraconozole because of toxicity (rash), five patients discontinued ketaconazole (two nausea, two hepatotoxicity and one rash). Despite successful clinical and mycological clearance, 80% patients had a further episode of candidosis within the next 3 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|